Molecules and Methods of Using Same for Treating MCP-1/CCR2 Associated Diseases

A molecule comprising an immunoglobulin sequence conjugated to a CCR2 amino acid sequence being capable of binding MCP-1, and wherein the molecule is non immunogenic and is devoid of an N-terminus domain of CCR2.

A pharmaceutical composition comprising the molecule of claim 1 and a pharmaceutically acceptable carrier.

A method of treating an MCP-1/CCR2 associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the molecule of claim 1, thereby treating the MCP-1/CCR2 associated disease in the subject.

A molecule comprising a CCR2 amino acid sequence attached to a non-proteinaceous moiety, wherein said CCR2 amino acid sequence is capable of binding MCP-1 and whereas the molecule is non-immunogenic in a subject.

A molecule comprising at least two CCR2 amino acid sequences each being capable of binding MCP-1.

A molecule comprising a tag attached to a CCR2 amino acid sequence devoid of an N-terminus domain of CCR2, said CCR2 amino acid sequence being capable of binding MCP-1.

A molecule as set forth in SEQ ID NO:

• 14 or 15.

A pharmaceutical composition comprising a molecule which comprises a CCR2 amino acid sequence devoid of an N-terminus domain of CCR2 and being capable of binding an MCP-1 and a pharmaceutically acceptable carrier, the pharmaceutical composition being non-immunogenic.

A method of treating an MCP-1/CCR2 associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a molecule which comprises a CCR2 amino acid sequence devoid of an N-terminus domain of CCR2 and being capable of binding an MCP-1, thereby treating the MCP-1/CCR2 associated disease in the subject.